Journal
MOLECULAR METABOLISM
Volume 6, Issue 5, Pages 440-446Publisher
ELSEVIER
DOI: 10.1016/j.molmet.2017.02.002
Keywords
Obesity; Sex differences; Diabetes; Glucose homeostasis; Dyslipidemia; Pharmacotherapy
Categories
Funding
- Alexander von Humboldt Foundation
- Helmholtz Alliance ICEMED-Imaging and Curing Environmental Metabolic Diseases through Initiative and Networking Fund of the Helmholtz Association
- Helmholtz cross-program topic Metabolic Dysfunction
- Helmholtz Initiative for Personalized Medicine (iMed)
- Deutsche Forschungsgemeinschaft [DFG-TS226/1-1, DFG: SFB1123-A4]
- Alfred Benzon Foundation
- DFG/MCT8 Defizienz Projekt [GZ TS226/ 3-1 AOBJ: 623001 [SPP1629]]
- Helmholtz Alliance ICEMED-Imaging and Curing Environmental Metabolic Diseases [WP 15]
- Lundbeck Foundation [R210-2015-4001] Funding Source: researchfish
Ask authors/readers for more resources
Objective: Obesity is a major health threat that affects men and women equally. Despite this fact, weight-loss potential of pharmacotherapies is typically first evaluated in male mouse models of diet-induced obesity (DIO). To address this disparity we herein determined whether a monomeric peptide with agonism at the receptors for glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon is equally efficient in correcting DIO, dyslipidemia, and glucose metabolism in DIO female mice as it has been previously established for DIO male mice. Methods: Female C57BL/6J mice and a cohort of fatmass-matched C57BL/6J male mice were treated for 27 days via subcutaneous injections with either the GLP-1/GIP/glucagon triagonist or PBS. A second cohort of C57BL/6J male mice was included to match the females in the duration of the high-fat, high-sugar diet (HFD) exposure. Results: Our results show that GLP-1/GIP/glucagon triple agonism inhibits food intake and decreases body weight and body fat mass with comparable potency in male and female mice that have been matched for body fat mass. Treatment improved dyslipidemia in both sexes and reversed diet-induced steatohepatitis to a larger extent in female mice compared to male mice. Conclusions: We herein show that a recently developed unimolecular peptide triagonist is equally efficient in both sexes, suggesting that this polypharmaceutical strategy might be a relevant alternative to bariatric surgery for the treatment of obesity and related metabolic disorders. (C) 2017 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available